RECODE THERAPEUTICS
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dy... skinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.
RECODE THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical Wellness
Founded:
2015-01-01
Address:
Dallas, Texas, United States
Country:
United States
Website Url:
http://www.recodetx.com
Total Employee:
51+
Status:
Active
Contact:
469-306-1618
Email Addresses:
[email protected]
Total Funding:
282 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics Google Universal Analytics Nginx Microsoft Exchange Online Office 365 Mail Nginx 1.14
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
Homology Medicines
Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.
Lyra Therapeutics
Lyra Therapeutics is a clinical-stage company developing medicines to treat ear, nose, and throat diseases.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Matrix Capital Management
Matrix Capital Management investment in Series B - ReCode Therapeutics
Leaps by Bayer
Leaps by Bayer investment in Series B - ReCode Therapeutics
Amgen Ventures
Amgen Ventures investment in Series B - ReCode Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - ReCode Therapeutics
Sanofi Ventures
Sanofi Ventures investment in Series B - ReCode Therapeutics
Colt Ventures
Colt Ventures investment in Series B - ReCode Therapeutics
Vida Ventures
Vida Ventures investment in Series B - ReCode Therapeutics
Sanofi Ventures
Sanofi Ventures investment in Series B - ReCode Therapeutics
OrbiMed
OrbiMed investment in Series B - ReCode Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - ReCode Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-25 | ReCode Enlists New CEO to Drive Assets into the Clinic |
| 2022-01-10 | ReCode Therapeutics names its CEO |
| 2021-09-27 | ReCode Therapeutics Appoints Nicholas P. France, M.D., as Senior Vice President of Clinical Development |
Official Site Inspections
http://www.recodetx.com Semrush global rank: 3.74 M Semrush visits lastest month: 3.62 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ReCode Therapeutics"
ReCode Therapeutics - Powering the future of genetic medicines …
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized …See details»
ReCode Therapeutics - Crunchbase Company Profile & Funding
ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics. Its selective organ targeting (SORT) lipid nanoparticle (LNP) platform …See details»
ReCode Therapeutics - LinkedIn
At ReCode Therapeutics, we're reshaping the future of Cystic Fibrosis (CF) treatment with our SORT LNP platform. Our clinical-stage candidate, RCT2100, targets the root cause of CF, particularly...See details»
ReCode Announces Two Key Additions to Scientific Advisory Board
Oct 1, 2024 · ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the …See details»
Recode Therapeutics - Overview, News & Similar companies
Jun 13, 2024 · ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs …See details»
ReCode Therapeutics to Expand Next-Generation …
Jun 29, 2022 · ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid...See details»
Cystic Fibrosis - ReCode Therapeutics
Using our SORT LNP platform, ReCode is targeting the underlying cause of the disease so that more people with CF may benefit. ReCode’s CFTR mRNA (RCT2100) is a clinical-stage candidate in development to treat the 10 percent …See details»
ReCode Therapeutics - VentureRadar
Website: https://recodetx.com Develops precision genetic medicines using a proprietary delivery platform for treatment of various genetic diseases, including cystic fibrosis and primary ciliary …See details»
ReCode Therapeutics Announces First Participants Dosed in a …
Feb 21, 2024 · Formulated using ReCode’s proprietary SORT LNP delivery platform, RCT2100 is an inhaled therapy designed to deliver CFTR mRNA to target cells and instruct them to make …See details»
ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study …
Jan 3, 2024 · ReCode has launched ThinkPCD.com, a program that provides genetic testing to PCD patients that qualify at no cost. Patients can enroll directly or through a healthcare …See details»
AskBio Announces Strategic Collaboration with ReCode …
Jan 9, 2023 · ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform …See details»
ReCode Announces Two Key Additions to Scientific Advisory Board
Oct 1, 2024 · ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the …See details»
ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study …
Jan 3, 2024 · Phase 1 study aims to evaluate safety and tolerability of a single ascending dose of RCT1100 in patients with PCD caused by mutations in the DNAI1 gene. RCT1100 is the first …See details»
ReCode Announces Two Key Additions to Scientific Advisory Board
Oct 1, 2024 · ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today …See details»
Unshackling genetic medicines byenablingdeliverybeyondtheliver
Harnessing its selective organ targeting lipid nanoparticle platform technology, ReCode Therapeutics is facilitating precision delivery of genetic cargos directly to their intended organs …See details»
ReCode Therapeutics to Present at Morgan Stanley 20
Sep 6, 2022 · ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs …See details»
Intellia Therapeutics and ReCode Therapeutics Announce Strategic ...
Feb 15, 2024 · ReCode will lead the subsequent preclinical and clinical development. ReCode will also lead worldwide commercialization for certain programs arising from the collaboration. …See details»
Texas Comptroller’s Office Releases Study on Organized Retail …
3 days ago · If ORT trends indicate a need, consider creating an organization to combat ORT modeled after or housed under the Texas Financial Crimes Intelligence Center. Finding 2: …See details»
ReCode Therapeutics Announces Strategic Collaboration with …
Jan 9, 2023 · ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs …See details»
Science - ReCode Therapeutics
Our selective organ targeting (SORT) lipid nanoparticles (LNPs) are engineered with a distinct fifth lipid to help the body “sort” and direct the LNPs to targeted organs with the ability to bypass …See details»